title: Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.
abstract: 1. The recombinant human prostaglandin D(2) (PGD(2)) receptor, hCRTH2, has been expressed in HEK293(EBNA) and characterized with respect to radioligand binding and signal transduction properties. High and low affinity binding sites for PGD(2) were identified in the CRTH2 receptor population by saturation analysis with respective equilibrium dissociation constants (K(D)) of 2.5 and 109 nM. This revealed that the affinity of PGD(2) for CRTH2 is eight times less than its affinity for the DP receptor. 2. Equilibrium competition binding assays revealed that of the compounds tested, only PGD(2) and several related metabolites bound with high affinity to CRTH2 (K(i) values ranging from 2.4 to 34.0 nM) with the following rank order of potency: PGD(2)>13,14-dihydro-15-keto PGD(2)>15-deoxy-Delta(12,14)-PGJ(2)>PGJ(2)>Delta(12)-PGJ(2)>15(S)-15 methyl-PGD(2). This is in sharp contrast with the rank order of potency obtained at DP : PGD(2)>PGJ(2)>Delta(12)-PGJ(2)>15-deoxy-Delta(12,14)-PGJ(2) >>>13,14-dihydro-15-keto-PGD(2). 3. Functional studies demonstrated that PGD(2) activation of recombinant CRTH2 results in decrease of intracellular cAMP in a pertussis toxin-sensitive manner. Therefore, we showed that CRTH2 can functionally couple to the G-protein G(alphai/o). PGD(2) and related metabolites were tested and their rank order of potency followed the results of the membrane binding assay. 4. By Northern blot analysis, we showed that, besides haemopoietic cells, CRTH2 is expressed in many other tissues such as brain, heart, thymus, spleen and various tissues of the digestive system. In addition, in situ hybridization studies revealed that CRTH2 mRNA is expressed in human eosinophils. Finally, radioligand binding studies demonstrated that two eosinophilic cell lines, butyric acid-differentiated HL-60 and AML 14.3D10, also endogenously express CRTH2.
authors.affiliation: Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada H9R 4P8.
authors.forename: Nicole
authors.initials: N
authors.lastname: Sawyer
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Cauchon
authors.forename: Anne
authors.initials: A
authors.lastname: Chateauneuf
authors.forename: Rani P G
authors.initials: RP
authors.lastname: Cruz
authors.forename: Donald W
authors.initials: DW
authors.lastname: Nicholson
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Metters
authors.forename: Gary P
authors.initials: GP
authors.lastname: O'Neill
authors.forename: Francois G
authors.initials: FG
authors.lastname: Gervais
mesh_terms: D001667:Binding, Competitive / Q000187:drug effects / Q000502:physiology; D002460:Cell Line; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D018922:HL-60 Cells; D006801:Humans; D012333:RNA, Messenger / Q000096:biosynthesis / Q000378:metabolism; D011971:Receptors, Immunologic / Q000819:agonists / Q000096:biosynthesis / Q000378:metabolism*; D011982:Receptors, Prostaglandin / Q000819:agonists / Q000096:biosynthesis / Q000378:metabolism* / Q000502:physiology; D011994:Recombinant Proteins / Q000378:metabolism / Q000494:pharmacology; D014162:Transfection
chemical_list: D012333:RNA, Messenger; D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin; D011994:Recombinant Proteins; C036293:prostaglandin D2 receptor